KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
Source: View publication →
The KEYNOTE-590 trial demonstrated that the addition of pembrolizumab to standard-of-care platinum-based chemotherapy significantly improves overall and progression-free survival in patients with previously untreated advanced or metastatic esophageal and esophagogastric junction (EGJ) cancers, regardless of histology or PD-L1 status.
Key Findings
Study Design
Study Limitations
Clinical Significance
KEYNOTE-590 established the combination of pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy as a new global standard of care for the first-line treatment of advanced or metastatic esophageal and Siewert type 1 EGJ carcinoma, demonstrating both a statistically significant and clinically meaningful improvement in long-term survival outcomes.
Historical Context
Prior to KEYNOTE-590, standard first-line therapy for advanced esophageal cancer was limited to platinum/fluoropyrimidine-based chemotherapy, which provided only modest survival benefits and carried a poor prognosis. The success of this trial represented a transformative shift in the treatment landscape by successfully integrating immune checkpoint inhibition into the frontline setting.
Guided Discussion
High-yield insights from every perspective
What is the physiological mechanism by which pembrolizumab enhances the anti-tumor response in patients with advanced esophageal cancer, and why is this often combined with chemotherapy?
Key Response
Pembrolizumab is a monoclonal antibody that blocks the PD-1 receptor on T-cells, preventing it from binding to ligands PD-L1 and PD-L2 on tumor cells. This disruption prevents the 'off signal' that tumors use to evade the immune system. Chemotherapy is added because it can induce immunogenic cell death, releasing tumor antigens and potentially sensitizing the tumor microenvironment to immunotherapy, thereby creating a synergistic effect.
Based on the KEYNOTE-590 results, which specific patient subgroups demonstrated the most significant overall survival benefit, and how does this influence your initial workup for a newly diagnosed metastatic esophageal cancer patient?
Key Response
While KEYNOTE-590 showed benefit in the all-comer population, the most pronounced survival benefits were seen in patients with Esophageal Squamous Cell Carcinoma (ESCC) and those with a PD-L1 Combined Positive Score (CPS) ≥ 10. Consequently, the initial workup must include both histological confirmation and mandatory PD-L1 IHC testing to risk-stratify the patient and set expectations for the magnitude of treatment benefit.
Evaluate the clinical significance of the KEYNOTE-590 findings for patients with Esophageal Adenocarcinoma (EAC) versus Esophageal Squamous Cell Carcinoma (ESCC) in the context of competing data from trials like CheckMate 648.
Key Response
KEYNOTE-590 included both EAC and ESCC, demonstrating benefit across histologies, whereas CheckMate 648 focused strictly on ESCC. Fellows must recognize that while PD-1 inhibition is now a standard for both, the magnitude of benefit in EAC (often found at the EGJ) may be slightly less robust than in ESCC. In EAC, integration with HER2 status (per KEYNOTE-811) further complicates the first-line landscape, necessitating a nuanced approach to biomarker-driven therapy.
How does the transition to first-line chemo-immunotherapy for advanced esophageal cancer alter your management of treatment-related toxicities, specifically when differentiating between chemotherapy-induced mucositis and immune-related adverse events?
Key Response
The addition of pembrolizumab adds a layer of complexity to toxicity management. An Attending must lead the team in distinguishing between cisplatin-induced nephrotoxicity or 5-FU-induced diarrhea and immune-mediated colitis or nephritis. Prompt recognition of immune-related adverse events (irAEs) is vital, as they require steroids and potential cessation of the checkpoint inhibitor, rather than simple dose reductions or supportive care used for cytotoxic side effects.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the hierarchical statistical testing strategy employed in KEYNOTE-590 and discuss how the multiplicity of primary endpoints (OS and PFS across various subgroups) affects the interpretation of the study's power and Type I error rate.
Key Response
KEYNOTE-590 used a complex gatekeeping procedure to control the family-wise error rate across multiple hypotheses (ESCC CPS ≥ 10, ESCC all, CPS ≥ 10 all, and all-randomized). This design is robust for regulatory approval but requires careful interpretation because the alpha is 'spent' across these groups. Researchers must consider whether the trial was truly powered for the smaller subsets or if the 'all-comer' benefit was driven primarily by the high-performing CPS ≥ 10 subgroup.
Assess the choice of 5-fluorouracil plus cisplatin as the control arm in KEYNOTE-590; does this choice limit the study's external validity in Western centers where FOLFOX is the preferred backbone?
Key Response
A critical reviewer would note that while 5-FU/Cisplatin was a global standard during trial design, many Western clinicians prefer FOLFOX due to its better tolerability profile (e.g., less emesis and nephrotoxicity). If the control arm is perceived as 'sub-optimal' or more toxic than current regional standards, it may slightly confound the perceived therapeutic index of the pembrolizumab-chemo combination, although subsequent data suggests the benefit of PD-1 inhibition is likely backbone-independent.
Considering the NCCN and ESMO guidelines, should pembrolizumab plus chemotherapy be recommended as a Category 1 preference for all patients with advanced esophageal cancer, or should it be restricted by CPS score?
Key Response
Current NCCN guidelines generally list pembrolizumab with chemotherapy as a Category 1 recommendation for first-line treatment. However, the strength of the recommendation is most robust for CPS ≥ 10. The committee must weigh the statistically significant OS benefit in the 'all-comer' group against the clinical meaningfulness of the benefit in the CPS < 1 population, where the hazard ratio often approaches 1.0, to decide if a 'preferred' status should be restricted to high-expressors.
Clinical Landscape
Noteworthy Related Trials
ATTRACTION-3
Tested
Nivolumab
Population
Patients with unresectable advanced or recurrent esophageal squamous-cell carcinoma refractory or intolerant to previous fluoropyrimidine and platinum-based chemotherapy
Comparator
Taxane chemotherapy (docetaxel or paclitaxel)
Endpoint
Overall survival
CheckMate 649
Tested
Nivolumab plus chemotherapy
Population
Patients with previously untreated advanced or metastatic gastric or gastro-oesophageal junction cancer
Comparator
Chemotherapy alone
Endpoint
Overall survival and progression-free survival
ESCORT-1st
Tested
Camrelizumab plus chemotherapy
Population
Patients with untreated advanced esophageal squamous cell carcinoma
Comparator
Placebo plus chemotherapy
Endpoint
Overall survival and progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis